BERGEN, Norway, Nov. 7, 2019 /PRNewswire/ -- BerGenBio ASA
(OSE:BGBIO), a clinical-stage biopharmaceutical company developing
novel, selective AXL kinase inhibitors for multiple cancer
indications, is pleased to announce it has been accepted for a
poster presentation at the 61st Annual American Society of
Hematology (ASH) Meeting, which takes place from 7-10 December 2019 in Orlando, Florida.
The poster will provide an update on its phase II study of
bemcentinib (BGB324) in combination with Low-dose Cytarabine in
elderly AML patients.
Abstract titles have been announced online. Details of the
presentation are below.
Title: Durable responses observed in elderly AML patients
unfit for intensive chemotherapy with first-in class selective AXL
inhibitor bemcentinib (BGB324) in combination with LDAC: Phase II
open-label study
Date: Monday 9th December
2019
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy,
excluding Transplantation: Poster III
Time, Location: 6:00 PM - 8:00
PM, Orange County
Convention Center, Hall B
About AXL
AXL kinase is a cell membrane receptor and an essential mediator
of the biological mechanisms underlying life-threatening diseases.
In cancer, AXL suppresses the body's immune response to tumours and
drives cancer treatment failure across many indications. AXL
inhibitors, therefore, have potential high value at the centre of
cancer combination therapy, addressing significant unmet medical
needs and multiple high-value market opportunities. Research has
also shown that AXL mediates other aggressive diseases.
About bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially
first-in-class selective AXL inhibitor in a broad phase II clinical
development programme. Ongoing clinical trials are investigating
bemcentinib in multiple solid and haematological tumours, in
combination with current and emerging therapies (including
immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular
catalytic kinase domain of AXL receptor tyrosine kinase and
inhibits its activity. Increase in AXL function has been linked to
key mechanisms of drug resistance and immune escape by tumour
cells, leading to aggressive metastatic cancers.
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused
on developing transformative drugs targeting AXL as a potential
cornerstone of therapy for aggressive diseases, including
immune-evasive, therapy resistant cancers. The company's
proprietary lead candidate, bemcentinib, is a potentially
first-in-class selective AXL inhibitor in a broad phase II oncology
clinical development programme focused on combination and single
agent therapy in lung cancer and leukaemia. A first-in-class
functional blocking AXL antibody (BGB149) and an AXL-ADC (ADCT-601)
are undergoing phase I clinical testing. In parallel, BerGenBio is
developing a companion diagnostic test to identify those patient
populations most likely to benefit from bemcentinib: this is
expected to facilitate more efficient registration trials
supporting a precision medicine-based commercialisation
strategy.
BerGenBio is based in Bergen,
Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo
Stock Exchange (ticker: BGBIO). www.bergenbio.com
Contacts
Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio
ASA
rune.skeie@bergenbio.com
+47 917 86 513
International Media Relations
Mary-Jane Elliott, Chris Welsh, Nicholas
Brown, Carina Jurs, Consilium
Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700
Media Relations in Norway
Jan Petter Stiff, Crux
Advisers
stiff@crux.no
+47 995 13 891
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/bergenbio-asa/r/bergenbio-to-present-clinical-data-from-phase-ii-combination-trial-of-bemcentinib-and-ldac-trial-in-,c2956262
The following files are available for download:
https://mb.cision.com/Main/15728/2956262/1137460.pdf
|
Release
|